Metabolic Factors of Outcomes From Gastric Bypass Surgery

NCT ID: NCT01347840

Last Updated: 2012-05-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine whether the metabolic, endocrine and energetic response to short term caloric restriction are factors in weight loss in subjects having gastric bypass (GB) surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All Subjects

This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects satisfying the following criteria will be considered the screening population and will be eligible for enrollment in this study:

1. Subject is willing to give consent and comply with evaluation and treatment schedule
2. 18 to 65 years of age (inclusive) on date of signing the ICD
3. Subject is scheduled to have non-revisional GB surgery between 2 weeks to 4 months after signing the ICD
4. Able to read, understand, and follow study procedures as outlined in the ICD.

Exclusion Criteria

Subjects meeting the following criteria will not be eligible for enrollment:

1. Unable or unwilling to attend follow-up visits and examinations
2. Women who are pregnant, nursing at the time of screening, or planning to become pregnant within one year of the GB surgery
3. Clinically active cardiac, renal, hepatic or GI disorders
4. Screening laboratory tests with any of the following:

* alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\] ≥ 4 times upper limit of normal (ULN) according to VAMC normal ranges
* AST:ALT \> 2:1 according to VAMC normal ranges
* Serum Creatinine ≥ 1.5 times ULN according to VAMC normal ranges
* Blood Urea Nitrogen (BUN) ≥ 1.5 times ULN according to VAMC normal ranges
* Positive test results for Hepatitis A, B or C
5. Clinically active thyroid or lipid disorders:

* Thyroid-stimulating hormone (TSH) flagged as critical value (per VAMC lab normal ranges)
* Triglycerides \> 400 mg/dL
6. Anemia:

* Mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) outside normal VAMC range; or
* Hematocrit \< 36%
7. Uncontrolled hypertension which required a medication regimen adjustment during the 3 months prior to screening
8. Currently prescribed or taking atypical antipsychotic medication
9. Currently prescribed or taking chronic, long-term, oral corticosteroid medication
10. Diabetes requiring a drug regimen which includes insulin treatment at the time of screening
11. Unwilling or unable to refrain from having a procedure or surgery which involves the removal of skin tissue which could result in weight loss
12. Any medical condition or finding for which the PI used medical discretion to determine the subject should be excluded; or
13. Participation in any other investigational device or drug study (non survey based trial) during the course of the trial.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ethicon Endo-Surgery

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David D'Alessio, MD

Role: PRINCIPAL_INVESTIGATOR

Veterans Affairs Medical Center, Cincinnati, OH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Veterans Affairs Medical Center

Cincinnati, Ohio, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CI-10-0004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.